New Diabetes Therapy Development Will Reach Key Congress

Researchers will discuss progress on a cell-based treatment for Type 1 diabetes this October in Philadelphia.

Updated on Sept. 28, 2026 in Diabetes

Bold flat-color editorial illustration featuring an abstract medical vial and cellular structure, evoking medical research and institutional scientific development. — NewcelX executives will present clinical trial progress for their NCEL-101 diabetes therapy at the Breakthrough T1D Research Congress in Philadelphia this October. AI Illustration. Upload story photo >

Live Poll

Do you feel optimistic that new stem-cell-derived therapies will soon provide functional cures for diabetes?

Executives from NewcelX will share updates on their NCEL-101 therapy during the Breakthrough T1D Clinical & Research Congress held October 9-11, 2026. This therapy is currently in development as a potential way to restore insulin production for people with Type 1 diabetes.

Why it matters

The company is working toward an Investigational New Drug application for a novel approach that could change long-term treatment strategies for those requiring insulin. This milestone follows recent regulatory feedback regarding their development path.

NewcelX is conducting preclinical and manufacturing activities to support a Phase 1/2a clinical trial, currently in the IND-enabling phase. It remains unknown when the formal application for human testing will be finalized and submitted.

The players

NewcelX

A publicly traded company focusing on stem-cell-based treatments for Type 1 diabetes.

FDA

The federal agency responsible for overseeing the safety and efficacy of medical products and clinical trials.

Breakthrough T1D

An organization dedicated to funding and facilitating research to treat and cure Type 1 diabetes.

The details

The experimental NCEL-101 therapy is designed to address the underlying cause of Type 1 diabetes by replacing lost pancreatic islet cells. To protect these implanted stem-cell-derived cells from immune system rejection, the treatment incorporates tegoprubart, an anti-CD40L antibody. This dual-action approach aims to restore the body's natural insulin production while managing the immune response.

July 2026: NewcelX held a Type B Pre-IND meeting with the FDA.
September 28, 2026: NewcelX announced its planned attendance at the upcoming congress.
October 9-11, 2026: Management will attend the Breakthrough T1D Congress in Philadelphia.

Health Landscape

The development of NCEL-101 is part of a growing field of regenerative medicine aimed at moving beyond standard insulin replacement therapy. This effort follows a long-standing historical arc in diabetes research focused on successfully implanting insulin-producing cells without triggering immune rejection.

This therapy is still in the experimental phase and is not currently available for patient use. Those interested in potential future options should discuss evolving research in islet cell transplantation and immune modulation with their endocrinologist.

The takeaway

The pursuit of cell-replacement therapies represents a significant potential shift in how Type 1 diabetes may be managed in the future. Readers should continue to monitor updates through their clinical care team regarding when and if new treatment modalities reach clinical trials.